Background:: The cytokine interferon beta (IFNβ) is successfully used in the treatment of multiple sclerosis (MS), although there is a high degree of variability in the response. A common mechanism involved in the modulation of responsiveness to cytokines is represented by regulation of their receptor expression through autocrine ligand-mediated loops. The present study is aimed at investigating the regulation of IFNα/β receptor (IFNAR) during IFNβ therapy in patients with MS and at correlating it with the biologic responsiveness to the cytokine. Methods:: Quantitative PCR measurements of IFNAR-1 and the three IFNAR-2 isoforms were performed in 141 patients after short-term and long-term treatment. Patients were also regularly screened for anti-IFNβ neutralizing antibodies (NAbs). IFN-inducible myxovirus resistance protein A messenger RNA was used as an indicator of bioactivity. Results:: Pretreatment levels of IFNAR-2 in patients were lower overall than in controls (p = 0.038), and high levels correlated with greater bioactivity. Upon prolonged treatment, NAb-negative patients displayed a state of decreased transmembrane IFNAR-2 expression (p ≤ 0.025), whereas levels of soluble IFNAR-2 were slightly increased (p < 0.0001). The presence of NAbs reversed these effects (p ≤ 0.0056). In NAb-positive patients, pretreatment expression levels of both transmembrane IFNAR-2 isoforms were significantly lower than in NAb-negative patients (p ≤ 0.0089). Conclusions:: Findings show that interferon-α/β receptor (IFNAR)-2 isoforms are important regulators of the responsiveness to endogenous and systemically administered interferon beta (IFNβ). They show a dual action, agonistic and antagonistic, that influences both the magnitude and the nature of the biologic response to IFNβ. Levels of IFNAR-2 are regulated with the aim of keeping the body in a state of equilibrium, even when nonphysiologic stimuli are present. Copyright © 2008 AAN Enterprises, Inc.
Expression and regulation of IFNα/β receptor in IFNβ-treated patients with multiple sclerosis
Gilli F.;Valentino P.;Capobianco M.;Marnetto F.;
2008-01-01
Abstract
Background:: The cytokine interferon beta (IFNβ) is successfully used in the treatment of multiple sclerosis (MS), although there is a high degree of variability in the response. A common mechanism involved in the modulation of responsiveness to cytokines is represented by regulation of their receptor expression through autocrine ligand-mediated loops. The present study is aimed at investigating the regulation of IFNα/β receptor (IFNAR) during IFNβ therapy in patients with MS and at correlating it with the biologic responsiveness to the cytokine. Methods:: Quantitative PCR measurements of IFNAR-1 and the three IFNAR-2 isoforms were performed in 141 patients after short-term and long-term treatment. Patients were also regularly screened for anti-IFNβ neutralizing antibodies (NAbs). IFN-inducible myxovirus resistance protein A messenger RNA was used as an indicator of bioactivity. Results:: Pretreatment levels of IFNAR-2 in patients were lower overall than in controls (p = 0.038), and high levels correlated with greater bioactivity. Upon prolonged treatment, NAb-negative patients displayed a state of decreased transmembrane IFNAR-2 expression (p ≤ 0.025), whereas levels of soluble IFNAR-2 were slightly increased (p < 0.0001). The presence of NAbs reversed these effects (p ≤ 0.0056). In NAb-positive patients, pretreatment expression levels of both transmembrane IFNAR-2 isoforms were significantly lower than in NAb-negative patients (p ≤ 0.0089). Conclusions:: Findings show that interferon-α/β receptor (IFNAR)-2 isoforms are important regulators of the responsiveness to endogenous and systemically administered interferon beta (IFNβ). They show a dual action, agonistic and antagonistic, that influences both the magnitude and the nature of the biologic response to IFNβ. Levels of IFNAR-2 are regulated with the aim of keeping the body in a state of equilibrium, even when nonphysiologic stimuli are present. Copyright © 2008 AAN Enterprises, Inc.
| File | Dimensione | Formato | |
|---|---|---|---|
|
gilli-et-al-2008-expression-and-regulation-of-ifnα-β-receptor-in-ifnβ-treated-patients-with-multiple-sclerosis.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
391.8 kB
Formato
Adobe PDF
|
391.8 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
